About ALTATHERA PHARMACEUTICALS LLC
AltaThera Pharmaceuticals develops intravenous cardiovascular therapies for the treatment of cardiac arrhythmias, including atrial fibrillation, atrial flutter, and life-threatening ventricular arrhythmias in both adult and pediatric patients. The company's Sotalol IV received FDA approval for new pediatric indications in July 2025.
Development of intravenous antiarrhythmic therapiesPersonalized dosing for cardiovascular treatmentRapid therapeutic assessment for cardiac conditionsFDA-approved therapies for both adult and pediatric patients
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to ALTATHERA PHARMACEUTICALS LLC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.